Burkitt's lymphoma medical therapy

Burkitt's lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Burkitt's lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study Of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
X Ray Findings
CT
MRI
Biopsy
Other Imaging Studies
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Burkitt's lymphoma medical therapy On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Burkitt's lymphoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Burkitt's lymphoma medical therapy
CDC on Burkitt's lymphoma medical therapy
Burkitt's lymphoma medical therapy in the news
Blogs on Burkitt's lymphoma medical therapy
Directions to Hospitals Treating Burkitt's lymphoma
Risk calculators and risk factors for Burkitt's lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

Medical Therapy

• Drug Regimen: CODOX-M-Cyclophosphamide, AND Vincristine, AND Doxorubicin, AND Methotrexate
• Drug Regimen: IVAC – (given after or alternated with CODOX-M)Ifosfamide PLUS Mesna, AND Etoposide, AND Cytarabine

Read more: http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/burkitt-lymphoma/?region=on#ixzz3n44mw14b

Chemotherapy

• cyclophosphamide
• doxorubicin
• vincristine
• methotrexate
• cytarabine
• ifosfamide
• etoposide

References

Template:WikiDoc Sources